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Abstract  Local  tumor  recurrence  after  thermal  ablation  of  hepatocellular  carcinoma  (HCC)
can impact  on  overall  survival  and  are  very  closely  linked  to  partial  treatment  of  the  primary
lesion or  to  potential  microvascular  invasion  or  satellite  micronodules  located  close  to  the
main lesion.  The  diagnosis  of  these  liver  metastases  close  to  the  primary  lesion  on  CT  and  MRI  is
difﬁcult and  their  incidence,  number  and  spread  throughout  the  liver  correlates  with  diameter
of primary  tumor.  Tumor  diameter  is  currently  the  key  factor  to  predict  whether  or  not  thermal
ablation of  HCC  will  be  complete  or  not.  It  has  now  been  shown  for  monopolar  radiofrequency
ablation that  this  therapy  alone  is  sufﬁcient  to  effectively  treat  single  HCCs  <  3  cm  in  diameter
provided  that  liver  micrometastases  are  not  present.  If  the  HCC  is  >3  cm  in  size,  multifocal  or  in
the case  of  tumor  recurrence,  overall  survival  and  recurrence-free  survival  results  are  better  if
monopolar radiofrequency  ablation  is  combined  with  hepatic  trans-arterial  chemoembolization.
The timing  of  this  combination  of  treatments  probably  inﬂuences  its  effectiveness  on  tumor  and
tolerability  and  remains  to  be  assessed.© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.∗ Corresponding author.
E-mail address: chevallier.p@chu-nice.fr (P. Chevallier).
http://dx.doi.org/10.1016/j.diii.2015.04.006
2211-5684/© 2015 Éditions franc¸aises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
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At  the  start  of  the  2000s,  hepatocellular  carcinoma  (HCC)
as  the  sixth  most  common  cancer  in  the  world,  with
26,000  new  cases  each  year,  and  was  the  third  leading  cause
f  cancer  deaths  [1].  In  more  than  80%  of  cases,  it  develops
n  a  patient  with  chronic  cirrhotic  liver  disease  and,  as  such,
irrhosis  may  be  thought  of  as  a  pre-malignant  state  [2].  The
wo  main  causes  of  the  related  liver  disease  in  France  are
iral  hepatitis  C  and  chronic  alcoholism.
Overall  survival  remains  poor  as  the  tumors  are  usually
ound  at  an  advanced  stage,  in  which  case  median  sur-
ival  is  under  six  months  [2].  Nevertheless,  in  less  advanced
tages,  curative  or  palliative  treatments  with  surgery,  inter-
entional  radiology  and  medical  treatments  with  targeted
herapy  can  be  offered  and  achieves  median  overall  survival
imes  of  several  years.
There  are  many  classiﬁcations  available  to  group  patients
ccording  to  the  state  of  progression  of  the  hepatic  and
xtra-hepatic  tumor  disease  and  according  to  liver  function.
one  of  these  have  been  universally  validated,  although  the
arcelona  classiﬁcation  (Barcelona  Clinic  Liver  Classiﬁcation
BCLC])  [3]  is  the  most  widely  used.  This  is  a  decision-making
lgorithm,  which  proposes  treatment  options  depending  on
he  stage  of  the  malignancy,  liver  function  and  the  patient’s
eneral  health.  Interventional  radiology  with  hepatic  trans-
rterial  chemoembolization  (TACE)  and  local  destruction  are
xtensively  used  to  treat  HCCs  from  the  very  early  stage
stage  0)  to  intermediary  (stage  B)  and  even  advanced  stage
stage  C).
HCCs  under  2  to  3  cm  in  diameter  can  be  classiﬁed  as
ery  early  stages  of  disease  (under  2  cm)  or  early  stages
BCLC  stage  A)  for  patients  in  good  general  health  with  pre-
erved  hepatocellular  function.  These  HCCs  can  be  treated
rst  line  or  after  postoperative  recurrence  by  thermal  abla-
ion,  which  produces  identical  results  in  terms  of  local  tumor
ontrol  with  less  morbidity  [4,5].  Thermal  ablation  is  also
ore  often  viable  than  surgery,  particularly  because  of  the
imitations  imposed  by  the  concomitant  liver  disease.  As
n  example,  a  recent  literature  review  reports  possible
urgery  viability  for  recurrent  HCCs  of  between  10.4  and
1%  [6].
HCCs  over  3  cm  in  diameter  can  be  classiﬁed  as  early
tage  if  they  are  single  or  intermediary  (BCLC  stage  B)  for
ultifocal  disease.  In  these  patients,  both  thermal  ablation
echniques  and  surgical  excision  are  associated  with  greater
ocal  recurrence  rates  with  increasing  tumor  diameter.  The
umor  diameter  itself  is  related  to  two  main  factors,  which
romote  recurrences:  vascular  micro-  or  macroinvasion  and
atellite  micronodules.  A  tumor  recurrence  rate  of  at  least
0%  is  seen  5  years  after  curative  treatment  [7]  because
f  these  intra-hepatic  metastases,  partial  treatment  of  the
ain  lesion  or  the  carcinogenesis  inherent  to  the  cirrhotic
iver  [8]  (Fig.  1).
BCLC  classiﬁcation  intermediary  HCCs  are  mostly  treated
rst  line  with  TACE  since  the  meta-analysis  published  by
lovet  et  al.  in  2003  which  showed  a  2-year  survival  ben-
ﬁt  for  patients  treated  with  TACE  compared  to  supportive
are  [9].  Treatment  however  is  usually  incomplete  and  the
omplete  tumor  necrosis  percentage  rates  are  between  10
nd  20%,  with  a  5-year  survival  rate  of  under  20%  [10,11].
There  is  a  rationale  for  combining  thermal  ablations
echniques  with  TACE  in  order  to  increase  percentage  com-
lete  tumor  response  rates  and  reduce  local  recurrences
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ue  to  inadequate  treatment  of  the  tumor  itself  or  of  its
eighbouring  environment.
This  article  reviews  the  rationale  for  this  treatment  com-
ination,  the  practical  aspects  of  its  use  and  its  preclinical
nd  clinical  results.  In  our  conclusion,  we  propose  an  algo-
ithm  for  using  this  treatment  combination.
ationale of the treatment combination of
hermal ablation and TACE to treat HCCs
ost  tumor  recurrences  following  surgical  excision  of  an
CC  within  the  segment  adjacent  to  the  excision  arise
rom  portal  spread  of  the  tumor,  which  can  be  prevented
y  a  wide  excision  margin  [7]. In  the  retrospective  study
eported  by  Poon  et  al.  [7]  surgical  excision  with  a  margin
f  over  10  mm  was  associated  with  the  same  number  of  local
ecurrences  as  a  margin  of  under  10  mm  and  in  addition  to
hese  occurrences  usually  occurred  within  the  year  follow-
ng  surgery  in  one  or  more  adjacent  segments  rather  than
long  the  line  of  the  liver  division,  suggesting  that  their  ori-
in  is  usually  due  to  intra-hepatic  metastases  or  multifocal
arcinogenesis.
These  intra-hepatic  metastases  are  due  to  microvascular
nvasion  or  microsatellite  nodule  (MSN),  which  are  occasion-
lly  confused  and  are  subsumed  into  the  same  entity  [12].
hey  correlate  with  the  extent  of  tumor  differentiation  and
lpha  fetoprotein  (AFP)  levels  [12]  and  also  with  survival.
he  ﬁve  year  survival  rate  for  HCCs  under  5  cm  treated  sur-
ically  has  been  reported  to  be  75.9%  in  patients  who  did  not
ave  intra-hepatic  metastases  and  54.1  and  20.5%  respec-
ively  if  metastases  under  or  over  5  mm  from  the  primary
umor  respectively  [12].
icrosatellite nodules (MSNs)
hese  are  seen  in  13  to  17%  of  cases  of  HCCs  under  2  cm
n  diameter  [13,14],  in  16.7%  to  27.2%  in  those  under  3  cm
14,15].  These  percentage  ﬁgures  increase  with  diameter
nd  extent  of  tumor  differentiation  [14,15]. One  study,  for
xample,  showed  that  they  could  be  present  in  up  to  72%  of
ases  of  HCCs  with  a  median  diameter  of  8.5  cm  [16]  and  are
eported  to  occur  more  previously  with  concomitant  hepati-
is  C  than  with  hepatitis  B  [17,18].  They  are  usually  located
t  least  1  cm  from  the  primary  tumor  but  may  be  further
way  with  increasing  tumor  diameter  [12].  They  have  been
ound  1.1  to  2  cm  from  the  primary  tumor  in  17%  of  cases  of
umors  under  3  cm  in  size  [15]  and  may  be  almost  4  cm  from
umors  under  5  cm  in  diameter  [12]. They  measured  a  few
illimeters  in  diameter  [15]  and  were  multiple  in  80%  of  the
ases  described  in  the  study  reported  by  Okusaka  et  al.  [14].
hey  usually  obtain  their  vascular  supply  from  the  same
ource  as  the  periphery  of  the  primary  tumor,  where  angio-
enesis  is  also  most  active,  particularly  in  tumors  under  5  cm
n  diameter  [16,17].  As  a  rule,  the  MSNs  are  therefore  very
ichly  supplied  by  the  hepatic  arterial  system  enabling  them
o  be  diagnosed  by  pre-treatment  imaging  [19,20]  although
he  diagnostic  accuracy  of  imaging  for  these  MSNs  has  not
een  extensively  studied.  One  recent  retrospective  study
ssessing  MRI  in  HCCs  measuring  an  average  of  2.8  to  3.2  cm
n  diameter  revealed  MSNs  in  7.0  to  11.1%  of  cases  [19]. It  is
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In order  to  reduce  the  percentage  of  local  recurrences,Figure 1. Risk factors for recurrence of intra-hepatic tumor afte
very  likely  that  imaging  methods  are  relatively  poorly  sensi-
tive  for  these  lesions  although  are  highly  speciﬁc  because  of
the  tumors’  rich  arterial  vascularization  despite  their  small
volume.  In  our  experience,  arteriography  performed  during
TACE  and  CT  to  monitor  lipiodol  arteriography  appears  to
be  more  sensitive  than  imaging  alone  in  making  a  diagnosis
(Fig.  2).
Vascular microinvasion
This  term  includes  a  broad  spectrum  of  histological  condi-
tions  ranging  from  tumor  invasion  of  a  single  vessel  close
to  the  capsule  of  the  tumor  to  macroscopic  vascular  tumor
invasion  [20].
This  type  of  vascular  invasion  inﬂuences  prognosis.  Llovet
et  al.  showed  that  microvascular  invasion  in  explanted  liver
was  associated  with  no  survival  without  tumor  recurrence
at  three  years  whereas  94%  of  patients  with  no  micro-  or
macrovascular  invasion  on  the  explanted  liver  had  no  tumor
recurrence  at  three  years  [21].
Tumor  diameter  clearly  inﬂuences  the  incidence  of  this
type  of  tumor  extension.
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Figure 2. Fifty-four year old man with cirrhosis from chronic hepatitis C
hepatocellular carcinoma, 25 mm in size, at the tip of the left lobe. a: ga
showing washout from the tumor and a more intense crown around the tu
shows no microsatellite nodules; b: lipiodol arteriography during hypers
lipiodol into the veins on the periphery of the tumor and two centimete
lesion; c: enhanced computed tomography 15 days after Lipiodol arter
primary lesion and more remotely in the right liver suggesting microsatemal destruction of a hepatocellular carcinoma (HCC).
Vascular  microinvasion  is  seen  in  25%  of  cases  of  tumors
nder  2  to  3  cm  in  size,  in  40  to  50%  of  tumors  under  5  cm  and
n  55%  of  tumors  over  6.5  cm  [20,22,23].  Tumor  diameter  and
umber  of  tumors,  however,  have  no  impact  on  survival  if
o  microvascular  invasion  is  present  [24].  Other  factors  such
s  multifocal  disease  or  an  AFP  of  over  1000  ng/mL  are  also
actors,  which  are  associated  with  vascular  microinvasion
23].
This  can  be  suspected  on  imaging,  showing  enhance-
ent  of  a  crown  around  the  tumor  or  of  hepatic  tissue
round  the  tumor  in  the  arterial  phase  of  gadolinium
nhancement  on  T1  weighted  MRI  or  CT  performed  dur-
ng  liver  arteriography,  demonstrating  arterio-portal  ﬁstulae
ithin  the  tumor  on  CT  during  hepatic  arteriography  or
y  measuring  the  intra-tumor  diffusion  coefﬁcient  on  MRI
19,25—28]. The  diagnostic  value  of  each  of  these  signs,
owever,  is  not  known  and  a  regular  enhancement  around
he  tumor  (Fig.  2a),  appears  to  be  the  most  reliable  sign
25,27].he  entire  tumor  volume  and  region  around  the  tumor  which
ay  contain  metastases  therefore  needs  to  be  treated.
n  order  to  do  this,  it  is  possible  to  attempt  to  increase
 virus infection and a biopsy proven moderately well differentiated
dolinium-enhanced T1-weighted MRI axial view in the portal phase
mor which may represent vascular microinvasion. This investigation
elective catheterization of the left lobe of the liver. Migration of
r sized Lipiodol uptake sites above and to the right of the primary
iography. Conﬁrmation of lipiodol uptake on the periphery of the
llite nodules.
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Figure 3. Frontal reconstruction of a computed tomography
investigation performed during hepatic intra-arterial injection of
iodinated contrast medium and immediately following thermal abla-
tion of an HCC with a 4 cm deployable monopolar radiofrequency
needle. Considerable hypervascularization, a usual ﬁnding on the
periphery of the thermal ablation area, allowing chemoemboliza-
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of  retrospective  studies  which  have  or  have  not  compared
combination  with  radiofrequency  or  microwave  treatmention to be concentrated in this region.
he  destruction  volume  of  the  main  lesion  compared  to
hat  is  obtained  with  monopolar  radiofrequency  ablation
ystems.  Many  techniques  have  been  described,  such
s  the  parallel  use  of  several  bipolar  [29]  or  monopolar
30]  radiofrequency  needles,  some  microwave  systems
31]  or  a  combination  of  radiofrequency  ablation  and
lcoholization  [32].  Some  studies,  mostly  on  animals,
ave  also  assessed  potentiation  of  thermal  destruction
y  combining  it  with  a  targeted  therapy  [33,34]  or  with
rugs,  which  promote  cell  apoptosis  [35,36].  None  of  these
ombinations  however  have  been  assessed  in  great  detail
nd  in  addition  they  can  only  partially  treat  the  region
round  the  tumor  and  in  particular  are  not  very  effective  in
reating  metastases  located  further  away  from  the  primary
umor.
Adding  TACE  to  thermal  destruction  is  likely  to  treat  a
egmental  or  region  or  sector  around  the  primary  lesion
here  the  majority  of  MSNs  and  microvascular  invasions  are
oncentrated.  Combination  of  TACE  with  thermal  destruc-
ion  could  also  achieve  higher  destruction  volumes  than
hose  obtained  with  thermal  destruction  alone.  The  timing
f  the  combination  has  a  potential  impact  on  the  mechanism
f  action  of  this  treatment.  Carrying  out  thermal  destruc-
ion  before  TACE  could  help  to  increase  the  local  destruction
olume  by  reducing  thermal  microconvection  effects  due  to
umor  vascularization  and  reducing  diffusion  of  heat  within
he  tumor  [37].  The  heat  produced  by  thermal  destruction
ould  therefore  help  to  increase  the  cytotoxic  effects  of  the
ntimitotic  agent  injected  during  TACE.  Administering  TACE
mmediately  after  thermal  destruction  could  also  increase
ocal  destruction  but  in  this  case,  by  concentrating  the  drug
nd  emboli  in  the  hyperemic  crown  around  the  tumor  caused
y  thermal  destruction  [38—40]  SS  (Fig.  3).  The  additional
dvantage  of  this  second  chronological  option  would  be  in
a
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imultaneously  treating  possible  hemorrhage  after  the  ther-
al  destruction  [39].
reclinical results
any  animal  studies  have  been  published  assessing  histolog-
cal  changes  produced  if  thermal  ablation  is  combined  with
epatic  arterial  therapy  [41—47].
The  vast  majority  of  these  studies  have  assessed  ini-
ial  arterial  treatment  followed  by  thermal  ablation  and
nly  two  of  these  studies  have  assessed  thermal  ablation
dministered  ﬁrst,  followed  by  hepatic  arterial  therapy
44,45].  The  combination  of  these  two  treatments  achieves
reater  reduction  in  liver  or  tumor  volumes  than  those
btained  with  either  of  the  two  treatments  used  alone
43,44,46,47].  Administering  hepatic  arterial  therapy  ﬁrst
chieves  greater  liver  and/or  tumor  destruction  volumes
han  those  obtained  if  thermal  ablation  is  carried  out
rst  [44,45],  although  the  standard  deviations  of  the
estruction  volumes  appear  to  be  considerably  greater
f  arterial  therapy  is  carried  out  ﬁrst,  which  may  sug-
est  greater  variability  in  destruction  volumes  obtained
ith  the  arterial-thermal  destruction  sequences  and  there-
ore  poorer  pretreatment  prediction  of  the  destruction
olume.
In  addition,  the  effect  of  anti-cancer  drugs  can  be
ncreased  or  reduced  by  hyperthermia.  This  has  been
emonstrated  in  cell  and  animal  studies  with  intravenous
njection  of  chemotherapy  [36—38,48]. No  animal  studies,
owever,  are  available  which  have  assessed  the  impact  of
eat  on  the  cytotoxic  effect  of  the  drug  when  TACE  is  com-
ined  with  thermal  ablation.
This  treatment  combination  appears  to  be  more  effec-
ive  when  less  than  100  m  [44]  of  microparticles  or  Lipiodol
ltra  ﬂuide® (LUF—Guerbet)  [46]  are  used,  or  if  the  time
etween  the  two  treatments  is  short  [42].
Finally,  this  mixed  treatment  appears  to  be  well  toler-
ted,  although  some  studies  show  a  greater  post-treatment
ise  in  liver  enzymes.  This  does  not  however  have  any  clinical
onsequences  [43].
linical results
ince  the  ﬁrst  cases  reported  by  Rossi  et  al.  in  2000,
reatments  using  a  combination  of  thermal  ablation  and
emporary  hepatic  artery  occlusion  or  TACE  [49]  many  pub-
ications  have  assessed  this  type  of  combination.  These  are
epresented  principally  by  four  randomized  trials  [6,50—52]
nd  many  meta-analyses  [53—57]  some  of  which  however
ave  included  several  types  of  local  destruction  including
lcoholization,  radiotherapy  and  high  intensity  ultrasound
53]  (Figs.  4  and  5).
iming of the combination
n  all  of  the  randomized  trials  and  in  the  vast  majoritylone  [58—63],  TACE  was  performed  before  the  thermal
blation  and  only  one  group  has  assessed  the  reverse  order,
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Figure 4. Seventy-one-year-old man with post alcohol related cirrhosis in good general health with preserved hepatocellular function
and a 35 mm HCC, histologically well differentiated and developing in the left lobe of the liver: a: b1000 diffusion weighted MRI axial
image showing the HCC as a hyperintensity and a satellite micronodule; b: hepatic arteriography showing the hypervascularized HCC; c:
microwave thermal ablation (80 watts for 10 minutes) followed by selective TACE treatment sequence in the left lobe with 100—300 
diameter emboli loaded with 50 mg of doxorubicin; d: frontal reconstruction of a computed tomogram with intravenous iodinated iodine
enhancement performed six weeks after treatment. Dense thermal ablation region because of hemorrhagic necrosis, delineated by an
area of necrosis due to the arterial treatment. Overall the treatment region measures almost 70 mm in diameter; e: gadolinium-enhanced
T1-weighted axial MRI view at 6 months showing complete tumor response according to the modiﬁed RECIST criteria.
Figure 5. Eighty-year-old man with cirrhosis due to chronic hepatitis C virus infection with preserved hepatocellular function and histo-
logically well differentiated 80 mm HCC developing in the dome of the liver. The decision was taken to treat with TACE using 100—300 
diameter microspheres loaded with 50 mg of doxorubicin followed in the event of tumor response by thermal ablation: a: arteriography dur-
ing the ﬁrst TACE; b: arteriography during the second TACE performed before microwave thermal ablation showing partial devascularization
of the HCC; c: gadolinium-enhanced T1-weighted axial MRI view at 12 months showing complete tumor response according to the modiﬁed
RECIST criteria.
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ith  TACE  performed  immediately  after  thermal  ablation,
hich  was  also  delivered  with  temporary  balloon  obstruction
f  the  hepatic  artery  [39,40].  In  the  studies  in  which  TACE
as  performed  ﬁrst,  thermal  ablation  was  rarely  delivered
n  the  same  day  [50]  or  on  the  day  after  [61],  but  usually
wo  to  four  weeks  later  [6,58,59,62—64].
ffects on overall survival and
rogression-free  survival for HCCs over 3 cm
n size
andomized  trials  which  have  included  patients  with  uni-  or
ultifocal  HCCs  over  3  cm  in  size  [51],  or  under  5  cm,  due  to
ecurrences  [6]  have  reported  a  signiﬁcant  increase  in  one
ear  [6,51],  three  years  [6,51],  four  years  [51]  and  ﬁve  years
6]  overall  survival  when  the  combination  treatment  is  used
ompared  to  radiofrequency  ablation  alone.  Only  the  study
eported  by  Morimoto  et  al.  [50],  which  included  patients
ith  HCC  between  3  and  5  cm  in  size,  showed  no  beneﬁt  on
hree  years  overall  survival  when  the  combination  treatment
as  used.
This  combination  is  also  associated  with  a  signiﬁcant
ncrease  in  survival  without  intrahepatic  recurrence  [6,51]
r  without  further  progression  at  the  thermal  destruction
ite  [50].
These  results  in  favor  of  the  treatment  combination  are
lso  seen  in  non-randomized  studies  [40,60]  and  in  meta-
nalyses  [50,54,57].
ffects on overall survival and
rogression-free  survival for HCCs under 3 cm
n size
lthough  one  non-randomized  study  has  shown  an  increase
n  progression-free  survival  at  one,  three  and  ﬁve  years  with
he  treatment  combination  in  patients  with  HCCs  between
 and  3  cm  in  size  [58],  one  randomized  trial  which  included
atients  with  HCCs  of  mean  diameter  of  1.7  cm  ±  0.5  cm
howed  that  the  combination  of  TACE  and  radiofrequency
blation  offered  no  beneﬁt  in  terms  of  overall  survival  or
rogression-free  survival  at  one,  two,  three  and  four  years
ompared  to  radiofrequency  ablation  alone  [52].  This  lack
f  beneﬁt  of  the  combination  treatment  has  also  been
escribed  in  a  meta-analysis  [57]  and  may  be  explained  by
he  low  incidence  of  mns  or  microvascular  invasion  with
CCs  under  2  cm  in  size  when  the  tumor  and  per-tumor
estruction  volume  are  sufﬁcient  with  thermal  destruction
lone.
omplications
ll  of  the  reports  published  in  the  literature  are  consistent
n  ﬁnding  that  the  combination  of  TACE  and  thermal  destruc-
ion  is  not  associated  with  more  major  complications  or
ortality  than  thermal  destruction  alone  [6,50—52,58—63].
ne  meta-analysis  describes  a  3.7%  major  complication  rate
or  the  combination  of  TACE  and  thermal  ablation,  which  is
imilar  to  what  is  reported  for  thermal  ablation  alone  [56].
n  improvement  in  the  quality  of  life  of  patients  treated
a
t
p
rP.  Chevallier  et  al.
ith  the  combination  has  also  been  described,  particularly
s  a  result  of  the  lower  incidence  of  tumor  recurrence
nd  fewer  treatments  for  recurrence  [65].  However,  we
hould  probably  remain  very  cautious  in  treating  patients
ith  hepatocellular  dysfunction,  (Child-Pugh  class  B  [66])
s  there  is  a  potential  risk  of  decompensation  in  these
atients.
Minor  complications  such  as  pain,  vomiting,  deterioration
n  general  health  and  asymptomatic  laboratory  abnormal-
ties  have  still  not  been  assessed  in  detail;  it  is  possible
hat  the  treatment  combination  may  produce  more  minor
omplications  as  was  found  in  two  clinical  trials  which
howed  more  vomiting  [50]  or  discomfort  with  increase  in
he  length  of  hospital  stay  [52]  for  patients  who  received
he  treatment  combination.
The  timing  of  the  treatment  combination  has  an  impact
n  whether  or  not  bleeding  complications  develop.  TACE
dministered  immediately  after  thermal  ablation  reduces
he  bleeding  complications  which  may  occur  after  thermal
blation  because  of  the  embolization  which  is  performed
39,40];  with  the  reverse  order  and  when  thermal  destruc-
ion  is  not  followed  by  arterial  embolization,  post  thermal
estruction  perihepatic  hematomas  have  been  described  in
p  to  5.9%  of  cases  [59],  together  with  one  case  of  fatal
emoperitoneum  [58].
The  timing  may  also  be  important  in  controlling  the
ltimate  volume  destruction  obtained.  If  TACE  is  admin-
stered  24  hours  before  thermal  ablation  it  may  result
n  unpredictable  destruction  regions  with  large  diame-
ers  and  high  standard  deviations  as  was  described  in
he  study  by  Morimoto  et  al.  [50]  and  ultimately  pro-
ote  hepatic  decompensation  or  extensive  liver  infarction.
his  point  is  still  not  well  assessed  in  the  literature
s  the  two  treatments  have  usually  been  separated  by
everal  weeks,  probably  carrying  a  lower  risk  in  this
ase  as  the  tumor  destruction  volumes  have  rarely  been
eported.
roposed use of the HIACE-thermal
estruction combination
n  light  of  the  literature  analysis  and  from  our  experi-
nce,  we  offer  a  decision-making  algorithm  for  monopolar
adiofrequency  ablation  and/or  TACE  management  of
atients  with  HCCs  (Fig.  6)  for  those  patients  with
reserved,  Child-Pugh  A  hepatocellular  function  and
ood  general  health  with  a  performance  status  of  0.
his  is  based  on  the  initial  analysis  of  tumor  diam-
ter  and  the  macroscopic  multifocal  or  microscopic
ature  of  tumors  including  vascular  microinvasions  and
SNs.
Radiofrequency  ablation  may  be  offered  for  unifocal  HCC
nder  3  cm  in  size.  It  is  essential  however  to  ensure  on
retreatment  imaging  that  no  micrometastases  are  present
n  the  periphery  of  the  tumor;  if  these  are  present  or
re  suspected  on  the  basis  of  histologic  proof  of  poor
umoral  differentiation  or  of  high  AFP  level,  patients  should
referably  be  treated  with  a  combination  of  TACE  and
adiofrequency  ablation.
Treatment  of  hepatocellular  carcinomas  by  TACE  and  RFA  643
Figure 6. Decision making algorithm for the use of monopolar radiofrequency ablation (RFA) and/or hepatic trans-arterial chemoemboliza-
tion (TACE) depending on liver tumor factors in patients with hepatocellular carcinoma (HCC) and in good general health with preserved
hepatocellular state. PR: partial tumor response; CR: complete tumor response; SD: stable disease; PD: progressive disease.
Take-home  messages
• The  combination  of  hepatic  trans-arterial
chemoembolization  (TACE)  and  monopolar
radiofrequency  ablation  (RFA)  can  treat  some
patients  with  hepatocellular  carcinoma  (HCC)  more
effectively.
• This  combination  should  only  be  offered  to
patients  with  HCC  over  3  cm  or  who  have  liver
micrometastases,  regardless  of  the  diameter  of  the
primary  lesion.
• In  the  case  of  a  single  HCC  between  3  and  5  cm  in  size
or  with  multifocal  disease  falling  within  the  Milan
criteria,  the  combination  should  be  offered  and  one
or  two  sessions,  chosen  depending  on  the  timing
• In  single  HCC  over  5  cm  in  size  or  with  multifocal
disease  outside  of  the  Milan  criteria,  the  combination
can  also  be  offered,  but  with  one  or  more
neoadjuvant  TACE  and  RFA  secondarily  only  for
patients  who  respond  signiﬁcantly  to  neoadjuvant
treatment.
• This  type  of  combination  still  has  to  be  assessed,  in
particular  a  comparison  between  the  different
timings  and  results  depending  two  major
factors  inﬂuencing  for  local  recurrence:  vascular
microinvasion  and  microsatellite  nodules.
DIn  multifocal  HCCs  between  3  and  5  cm  in  size  remaining
within  the  Milan  criteria  (no  more  than  three  lesions,
and  under  3  cm  in  size),  patients  can  be  treated  ﬁrst
line  with  the  combination  of  TACE  and  radiofrequency
ablation  delivered  in  the  same  session  if  the  radiofre-
quency  ablation  is  performed  ﬁrst,  or  in  two  sessions
separated  by  a  few  days  or  weeks  if  the  TACE  is  performed
ﬁrst.
In  unifocal  HCC  over  5  cm  in  size  or  in  multifocal  disease
outside  of  the  Milan  criteria  but  within  the  indications  for
TACE,  one  or  several  TACE  may  be  delivered  on  a  neoad-
juvant  basis.  After  follow  up  imaging,  the  decision  as  to
whether  or  not  to  supplement  treatment  with  radiofre-
quency  ablation  will  be  based  on  the  tumor  response  as
assessed  according  to  the  modiﬁed  Recist  criteria  [67]  and
evaluating  the  extent  of  tumor  devascularization  [68]. If
the  response  obtained  is  partial  or  complete,  thermal  abla-
tion  may  be  offered  for  the  tumor  component,  which  is  still
vascularized.
Conclusion
The  combination  of  TACE  and  thermal  ablation  can  be
offered  to  many  patients  with  HCC  based  on  a  strong
rationale  and  with  a  good  level  of  preclinical  and  clini-
cal  scientiﬁc  evidence.  There  is  still,  however,  considerable
missing  information  such  as,  for  example,  the  clini-
cal  impact  of  the  choice  of  timing  or  the  value  of
major  recurrence  factors  such  as  vascular  microinvasion,
microsatellite  nodules,  the  degree  of  tumor  differentia-
tion  or  in  the  near  future,  oncogenetic  factors  on  its
indications.
T
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